Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemiralisib add-on dose-finding study in acute COPD exacerbation
NL-OMON46452Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Nemiralisib + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change from baseline in trough FEV1 at Day 84 measured post-bronchodilator. Started Jan 2018; status: active, not recruiting.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON46452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46452.